Online inquiry

IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2291MR)

This product GTTS-WQ2291MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Paroxysmal nocturnal hemoglobinuria (PNH) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2291MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1745MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ADCT-301
GTTS-WQ12605MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA NVS250519
GTTS-WQ8655MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA HuMax-CD38
GTTS-WQ9898MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA KB001-A
GTTS-WQ3428MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AV-299
GTTS-WQ14887MR IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SGN-LIV1A
GTTS-WQ5695MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ15795MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA XmAb-13676
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW